STAT January 17, 2025
Joe Grogan

Price controls are a surefire way to crush innovation

President Biden took a groundbreaking step in proposing to cover GLP-1 obesity medications under Medicare and Medicaid in November. But on Friday, his administration announced that Wegovy, one of these drugs, would be subject to price controls. This is a surefire way to crush innovation and discourage new entrants to this important new class of medicines that could help millions of Americans.

GLP-1s, or glucagon-like peptide-1 receptor agonists, are...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
Value-based payment models: Doctors describe the disconnect between theory and practice
Nurse anesthetists outnumber anesthesiologists billing Medicare
OIG report finds just 40% of Medicare enrollees who started treatment for opioid use disorder continued
Fewer psychiatrists are billing Medicare: 5 things to know
Psychiatrists participating in Medicare Part B declines: Study

Share This Article